Favourable effect of TNF-α inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation

APMIS

Volumn 114, Issue 12, 2006, Pages 912-919

  Milman, Nils ^a,c   Andersen, Claus B ^a   Hansen, Annette ^a   Van Overeem Hansen, Thomas ^a   Nielsen, Finn C ^a   Fledelius, Hans ^a   Ahrens, Peter ^b   Nielsen, Ole Haagen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Blau syndrome; CARD15 mutation; Infliximab; Monozygotic twins; TNF inhibitor

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; BLAU SYNDROME; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG EFFECT; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MONOZYGOTIC TWINS; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS; DISEASES IN TWINS; DNA; EXANTHEMA; HUMANS; MALE; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SYNDROME; TWINS, MONOZYGOTIC; UVEITIS;

EID: 33845707639     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2006.apm_522.x     Document Type: Article

References (26)

1. Blau EB. Familial granulomatous arthritis, iritis and rash. J Pediatr 1985;107:689-93.
2. Pastores GM, Michels VV, Stickler GB, Su WP, Nelson AM, Bovenmyer DA. Autosomal dominant granulomatous arthritis, uveitis, skin rash and synovial cysts. J Pediatr 1990;117:403-8.
3. Manouvrier-Hanu S, Puech B, Piette F, Boute-Benejean O, Desbonnet A, Duquesnoy B, et al. Blau syndrome of granulomatous arthritis, iritis, and skin rash: a new family and review of the literature. Am J Med Genet 1998;217-21.
4. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001;29:19-20.
5. Wang X, Kuivaniemi H, Bonavita G, Mutkus L, Mau U, Balu E, et al. CARD15 mutations in familial granulomatosis syndrome. Arthritis Rheum 2002;30:41-5.
6. Priori R, Bombardieri M, Spinelli FR, Merlin F, Miceli-Richard C, La Cava M, et al. Sporadic Blau syndrome with a double CARD15 mutation. Report of a case with lifelong follow-up. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:228-31.
7. Rose CD, Doyle TM, McIlvain-Simpson G, Coffman JE, Rosenbaum JT, Davey MP, et al. Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol 2005;32:373-5.
8. Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 2005;105:1195-7.
9. van Duist MM, Albrecht M, Podswiadek M, Giachino D, Lengauer T, Punzi L, et al. A new Card15 mutation in Blau syndrome. Eur J Hum Genet 2005;13:742-7.
10. Becker ML, Rose CD. Blau syndrome and related genetic disorders causing childhood arthritis. Curr Rheumatol Rep 2005;7:427-33.
11. Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, et al. CARD15/NOD2 mutational analysis and genotype phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70:845-57.
12. Schurmann M, Valentonyte R, Hampe J, Muller-Quernheim J, Schwinger E, Schreiber S. CARD15 gene mutations in sarcoidosis. Eur J Resp Dis 2003;22:748-54.
13. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005;172:519-21.
14. Andersen PS, Jespersgaard C, Vuust J, Christiansen M, Larsen LA. High-throughput single strand conformation polymorphism mutation detection by automated capillary array electrophoresis: validation of the method. Hum Mutat 2003;21:116-22.
15. Rybicki BA, Maliarik MJ, Bock CH, Elston RC, Baughman RP, Kimani AP, et al. The Blau syndrome gene is not a major risk factor for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:203-8.
16. Hoffmann L, Milman N, Byg KE. Childhood sarcoidosis in Denmark 1979-1994: incidence, clinical features and laboratory results in 48 children. Acta Paediatr 2004;93:30-6.
17. Masel G, Halbert A. Blau syndrome presenting with ichthyosis. Australas J Dermatol 2005;46:29-32.
18. Ting SS, Ziegler J, Fischer E. Familial granulomatous arthritis (Blau syndrome) with granulomatous renal lesions. J Pediatr 1998;133:450-2.
19. Hetherington S. Sarcoidosis in young children. Am J Dis Child 1982;136:13-5.
20. Pattishall EN, Kendig EL. Sarcoidosis in children. Pediatr Pulmonol 1996;22:195-203.
21. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001;276:4812-18.
22. Chamaillard M, Philpott S, Girardin SF, Zouali H, Lesage S, Chareyre F, et al. Gene-environment interaction moduled by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci USA 2003;100:3455-60.
23. Moller DR. Treatment of sarcoidosis - from a basic science point of view. J Intern Med 2003;253:31-40.
24. Fehrenbach H, Zissel G, Goldmann T, Tschernig T, Vollmer E, Pabst R, et al. Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis. Eur Resp J 2003;21:421-8.
25. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-71.
26. Wyser CP, van Schlakwyk EM, Alheit B, et al. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med 1997;156:1571-6.